Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
China Sandi Holdings Ltd
HKEX:910
|
HK |
|
Hillman Solutions Corp
NASDAQ:HLMN
|
US |
|
A
|
American Airlines Group Inc
BMV:AAL
|
US |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| TW |
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
121.9B TWD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
837.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
583.9B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
228B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
292.3B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
229.9B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
157.9B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD |
Loading...
|
Market Distribution
| Min | -197.7% |
| 30th Percentile | 13.7% |
| Median | 22.1% |
| 70th Percentile | 31.4% |
| Max | 400.8% |
Other Profitability Ratios
Caliway Biopharmaceuticals Co Ltd
Glance View
Caliway Biopharmaceuticals Co. Ltd. offers pharmaceutical services. The company is headquartered in Taipei, New Taipei. The company went IPO on 2022-12-26. The drugs developed by the Company are all small molecule drugs, including CBL-514, CBA-539, CBO-012 and CBF-520. CBL-514 is used for non-surgical local fat reduction, cellulite, Baergen's disease and lipoma and others. The company is in the second clinical stage. CBA-539 is used for pigmentation, whitening and anti-aging, and it is in the non-clinical research stage. CBO-012 is in the non-clinical research stage for degenerative arthritis. CBF-520 is used for central obesity and non-alcoholic fatty liver disease, and it is in the non-clinical research stage. The firm's sales revenue comes from health food, which is sold by agents and distributors, with Taiwan and China as the main sales areas.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Caliway Biopharmaceuticals Co Ltd is 69.7%, which is above its 3-year median of 61%.
Over the last 3 years, Caliway Biopharmaceuticals Co Ltd’s Gross Margin has decreased from 74.9% to 69.7%. During this period, it reached a low of 14.7% on Jun 30, 2024 and a high of 74.9% on Dec 1, 2022.
